TAp63: A New Protein Drug Target for Rheumatoid Arthritis

2023.05.23

Contents

Share

  • Share on Twitter
  • Share on Facebook
  • Share on LINE
  • Share with Hatena Bookmark

Methotrexate (MTX) is a first-line treatment in the fight against rheumatoid arthritis (RA)—an autoimmune disease characterized by joint deterioration. However, the precise therapeutic mechanisms of MTX are poorly understood. Now, researchers from Chiba University reveal that a variant of tumor protein p63, TAp63, is suppressed by MTX, which in turn suppresses the expression of another protein, Foxp3, and aggravates RA.

Click here for the press release.

Recommend

このページのトップへ戻ります